课题基金 / 基金详情

项目摘要

项目成果

Leo Luznik的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):这项提案的更广泛、更长期的目标是剖析过继转移的供者T细胞在给药后对已建立的同种异体嵌合体的同种免疫反应的机制,并利用这些数据开发临床可翻译的策略,以增强抗肿瘤免疫。我们的初步研究表明,在MHC相合的同种异体移植后,宿主来源的树突状细胞(DC)仍然存在于皮肤中,尽管血液中存在明显的全供者DC嵌合体和持续的移植物抗白血病(GVL)反应。此外,我们发现,将供者T细胞过继转移到所有血树突状细胞都来自供体的同种异体MHC相合嵌合体中,可以导致移植物抗宿主(GVH)对残留的宿主皮肤树突状细胞的反应性。有趣的是,给与Toll样受体(TLR)7配体咪喹莫德局部处理的嵌合体给予DLI,不仅增强了DLI介导的GVH反应,而且增强了GVL反应。这些反应,如果与肿瘤疫苗接种相结合,导致接受治疗的动物对肿瘤再次挑战表现出记忆反应的能力。因此,这一建议的中心假设是,供者T细胞/宿主皮肤DC相互作用在完全供者嵌合体移植后诱导同种免疫反应中发挥主要作用;此外,这些反应的结果可以通过限定的分子配体和肿瘤疫苗在体内操纵,从而产生持久的抗肿瘤免疫。为了研究这一假说,提出了以下具体目标:1)研究MHC相合同种异体移植后T细胞/DC相互作用的细胞和分子机制。这些研究将确定宿主和供体DC在DLI介导的GVH和GVL反应中的作用,以及TLR介导的信号转导的作用;以及2)确定T细胞/DC相互作用在同种异体移植后疫苗诱导的反应中的作用。这些研究将检验残留的宿主皮肤DC和供者血液DC在诱导抗原特异性T细胞和疫苗诱导免疫方面的功能意义。这项建议中描述的研究的近期目标是开发新的治疗策略,可能导致提高抗肿瘤免疫力;长期目标是将这些发现转化为临床。 公共卫生相关性:这一建议背后的中心假设是,供者T细胞和残留宿主皮肤DC之间的相互作用在完全供者嵌合体移植后诱导同种异体免疫反应中发挥主要作用,这些反应的结果可以通过确定的分子配体和肿瘤疫苗在体内操纵,从而产生长期的抗肿瘤免疫。因此,这项拟议研究的目标是剖析已建立的MHC匹配的同种异体嵌合体中控制同种免疫反应的机制,并利用这些数据来开发临床可翻译的策略,以增强抗肿瘤免疫。
英文摘要
DESCRIPTION (provided by applicant): The broader, long-term objectives of this proposal are to dissect the mechanisms governing alloimmune responses of adoptively transferred donor T cells after their administration to established allogeneic chimeras and to use this data to develop clinically translatable strategies to augment anti- tumor immunity. Our preliminary studies suggest that after MHC-matched allografting, host-derived dendritic cells (DCs) persist in the skin, despite the apparent full donor DC chimerism in the blood and ongoing graft-versus-leukemia (GVL) responses. Furthermore, we found that adoptive transfer of donor T cells to allogeneic MHC-matched chimeras, in which all blood DCs are of donor origin, can lead to graft-versus-host (GVH) reactivity toward residual host skin DCs. Interestingly, DLI administration to chimeras that have been topically treated with the Toll-like receptor (TLR)7 ligand, imiquimod, not only augmented the DLI-mediated GVH reactivity, but also the GVL response. These responses, if combined with tumor vaccination, resulted in the ability of treated animals to exhibit an anamnestic response to tumor re-challenge. Accordingly, the central hypothesis of this proposal is that donor T cell/host skin DC interactions play a principal role in the induction of an alloimmune response in complete donor chimeras post-transplant; and, moreover, that the outcome of these responses can be manipulated in vivo with defined molecular ligands and tumor vaccines to result in long-lasting anti-tumor immunity. To investigate this hypothesis, the following specific aims are proposed: 1) To characterize the cellular and molecular mechanisms governing T cell/DC interactions post MHC-matched allografting. These studies will determine the roles of host and donor DCs on the DLI-mediated GVH and GVL reactivities and characterize the role of TLR-mediated signaling; and 2) To determine the role of T cell/DC interactions on the vaccine-induced responses after allografting. These studies will examine the functional significance of residual host skin DCs and donor blood DCs on the induction of antigen-specific T cells and vaccine-induced immunity. The immediate goal of the studies described in this proposal is to develop novel therapeutic strategies that may lead to improved anti- tumor immunity; the long-term goal is to translate these findings to the clinic. PUBLIC HEALTH RELEVANCE: The central hypothesis behind this proposal is that interactions between donor T cells and residual host skin DCs play a principal role in the induction of alloimmune responses in complete donor chimeras post-transplant and that outcome of these responses can be manipulated in vivo with defined molecular ligands and tumor vaccine resulting in long-lasting anti-tumor immunity. Thus, the goal of the proposed study is to dissect the mechanisms governing alloimmune responses in established MHC- matched allogeneic chimeras and to use this data to develop clinically translatable strategies to augment anti-tumor immunity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Marrow-Infiltrating Lymphocytes
  • 批准号:
    10197002
  • 项目类别:
  • 资助金额:
    $24.39万
  • 财政年份:
    2019
  • 负责人:
    Leo Luznik
  • 依托单位:
Immune Monitoring Core
  • 批准号:
    10197008
  • 项目类别:
  • 资助金额:
    $35.47万
  • 财政年份:
    2019
  • 负责人:
    Leo Luznik
  • 依托单位:
Marrow-Infiltrating Lymphocytes
  • 批准号:
    10671622
  • 项目类别:
  • 资助金额:
    $17.71万
  • 财政年份:
    2019
  • 负责人:
    Leo Luznik
  • 依托单位:
Immune Monitoring Core
  • 批准号:
    10671632
  • 项目类别:
  • 资助金额:
    $25.76万
  • 财政年份:
    2019
  • 负责人:
    Leo Luznik
  • 依托单位:
海外基金